Chronic obstructive pulmonary disease is a risk factor for non-tuberculous mycobacterial pulmonary disease: a population-based matched cohort study
- PMID: 40541276
- PMCID: PMC12182194
- DOI: 10.1136/bmjresp-2024-002373
Chronic obstructive pulmonary disease is a risk factor for non-tuberculous mycobacterial pulmonary disease: a population-based matched cohort study
Abstract
Background: Longitudinal studies comprehensively evaluating the direction of the relationship between chronic obstructive pulmonary disease (COPD) and non-tuberculous mycobacterial pulmonary disease (NTM-PD) are scarce. Therefore, this study aimed to evaluate whether COPD influences the development of NTM-PD even after considering various confounders by using a nationwide longitudinal cohort study.
Methods: Data from the National Health Insurance Service National Sample Cohort between 2002 and 2019 were analysed. Participants≥20 years of age with COPD and no previous NTM diagnosis were included in the study. The incidence of NTM-PD was compared between participants with COPD (n=8939) and 1:4 fully matched control participants (n=32 355). Participants were followed until the date of NTM-PD incidence, death, or December 2019.
Results: During a median follow-up of 9.0 years (IQR, 5.0-12.9 years), participants with COPD (55.5 per 100 000 person-years) had a higher incidence of NTM-PD than matched control cohorts (25.4 per 100 000 person-years), with a HR of 2.16 (95% CI, 1.45 to 3.23). Age, sex, smoking history, asthma, bronchiectasis and corticosteroid use did not affect the association between COPD and the risk of incident NTM-PD (P for interaction >0.05 for all). Among patients with COPD, being underweight and having bronchiectasis were significantly associated with NTM-PD development.
Conclusions: Individuals with COPD had approximately a twofold increased risk of developing NTM-PD compared with matched controls. Being underweight and having bronchiectasis were identified as risk factors for developing NTM-PD.
Keywords: Atypical Mycobacterial Infection; COPD epidemiology; Pulmonary Disease, Chronic Obstructive.
© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.
Conflict of interest statement
Competing interests: None declared.
Figures
Similar articles
-
Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta-analysis.Cochrane Database Syst Rev. 2021 Jan 15;1(1):CD013198. doi: 10.1002/14651858.CD013198.pub2. Cochrane Database Syst Rev. 2021. PMID: 33448349 Free PMC article.
-
Computer and mobile technology interventions for self-management in chronic obstructive pulmonary disease.Cochrane Database Syst Rev. 2017 May 23;5(5):CD011425. doi: 10.1002/14651858.CD011425.pub2. Cochrane Database Syst Rev. 2017. PMID: 28535331 Free PMC article.
-
Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease.Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD009157. doi: 10.1002/14651858.CD009157.pub2. Cochrane Database Syst Rev. 2012. PMID: 22972134 Free PMC article.
-
Risk Factors and Long-Term Prognosis for Coinfection of Nontuberculous Mycobacterial Pulmonary Disease and Chronic Pulmonary Aspergillosis: A Multicentre Observational Study in Japan.Mycoses. 2025 Jun;68(6):e70083. doi: 10.1111/myc.70083. Mycoses. 2025. PMID: 40536274 Free PMC article.
-
Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or chronic obstructive pulmonary disease.Cochrane Database Syst Rev. 2022 Nov 14;11(11):CD013343. doi: 10.1002/14651858.CD013343.pub2. Cochrane Database Syst Rev. 2022. PMID: 36373977 Free PMC article.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical